Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH Work Group

Movement Disorders

Volumn 22, Issue 8, 2007, Pages 1061-1068

  Ravina, Bernard ^a,m   Marder, Karen ^b   Fernandez, Hubert H ^c   Friedman, Joseph H ^d   McDonald, William ^e   Murphy, Diane ^f   Aarsland, Dag ^g   Babcock, Debra ^f   Cummings, Jefferey ^h   Endicott, Jean ^b   Factor, Stewart ^e   Galpern, Wendy ^f   Lees, Andrew ⁱ   Marsh, Laura ^j   Stacy, Mark ^k   Gwinn Hardy, Katrina ^f   Voon, Valerie ^f   Goetz, Christopher ^l  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b Medical Center College of Physicians and Surgeons ^*  (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d BROWN UNIVERSITY   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^g STAVANGER UNIVERSITY HOSPITAL   (Norway)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l RUSH UNIVERSITY MEDICAL CENTER   (United States)

^m Rush University Medical Center ^*  (United States)

more..

Author keywords

Diagnosis; Parkinson's; Psychosis

Indexed keywords

NEUROTRANSMITTER;

CLINICAL FEATURE; COMORBIDITY; CONSENSUS; DEATH; DELUSION; DEMENTIA; DEPTH PERCEPTION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG INTOXICATION; HALLUCINATION; HUMAN; LEWY BODY; MEDICAL LITERATURE; MONOAMINE NERVE CELL; NURSING HOME; ONSET AGE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOMENOLOGY; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; RELIABILITY; REVIEW; SCHIZOPHRENIA; SYMPTOM; VALIDITY;

CONSENSUS; DIAGNOSIS, DIFFERENTIAL; EDUCATION; HUMANS; NATIONAL INSTITUTE OF MENTAL HEALTH (U.S.); PARKINSON DISEASE; PREVALENCE; PSYCHOTIC DISORDERS; PUBLISHING; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 34447577668     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21382     Document Type: Review

References (61)

1. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
2. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson disease. Arch Neurol 1996;53:1265-1268.
3. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:533-535.
4. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123 (Part 4):733-745.
5. Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson's disease. From description to etiology. J Neurol 2005;252:753-764.
6. Graham JM, Grunewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:434-440.
7. Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neurol 1993;60:703-706.
8. Marsh L, Williams JR, Rocco M, et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004;63:293-300.
9. Factor SA, Molho ES. Threatening auditory hallucinations and Cotard syndrome in Parkinson disease. Clin Neuropharmacol 2004;27:205-207.
10. Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 2001;16:528-536.
11. Barnes J, David AS. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 2001;70:727-733.
12. de Maindreville AD, Fenelon G, Mahieux F. Hallucinations in Parkinson's disease: a follow-up study. Mov Disord 2005;20:212-217.
13. Marsh L. Psychosis in Parkinson's disease. Curr Treat Options Neurol 2004;6:181-189.
14. Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson's disease. Mov Disord 2003;18:831-832.
15. Papapetropoulos S. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 2006;29:59.
16. Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 1998;51:811-814.
17. Wolters EC, Berendse HW. Management of psychosis in Parkinson's disease. Curr Opin Neurol 2001;14:499-504.
18. Wolters EC. Intrinsic and extrinsic psychosis in Parkinson's disease. J Neurol 2001;248 (Suppl 3):III22-III27.
19. Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol 2006;63:713-716.
20. Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 2001;57:2078-2082.
21. Pollak P, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomized, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75:689-695.
22. Fernandez HH, Trieschmann ME, Okun MS. Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease. Mov Disord 2005;20:104-105.
23. Factor SA, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003;60:1756-1761.
24. Aarsland D, Larsen JP, Karlsen K, Lim NG, Tandberg E. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999;14:866-874.
25. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000;48:938-942.
26. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-671.
27. Fernandez HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov Disord 2004;19:831-833.
28. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999;56:595-601.
29. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.
30. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70:734-738.
31. Giladi N, et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. J Neural Transm 2000;107:59-71.
32. Rippon GA, Marder KS. Dementia in Parkinson's disease. Adv Neurol 2005;96:95-113.
33. Fenelon G, Mahieux F. Hallucinations and dementia. Prevalence, clinical presentation and pathophysiology. Rev Neurol (Paris) 2004;160:S31-S43.
34. Aarsland D, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999;67:492-496.
35. Goodwin FK. Psychiatric side effects of levodopa in man. JAMA 1971;218:1915-1920.
36. Rascol O, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-1491.
37. Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-1938.
38. Herzog J, et al. Manic episode with psychotic symptoms induced by subthalamic nucleus stimulation in a patient with Parkinson's disease. Mov Disord 2003;18:1382-1384.
39. Herzog J, et al. Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. Mov Disord 2003;18:1332-1337.
40. Friedman A, Sienkiewicz J. Psychotic complications of long-term levodopa treatment of Parkinson's disease. Acta Neurol Scand 1991;84:111-113.
41. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000;15:201-211.
42. Fenelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson disease in the prelevodopa era. Neurology 2006;66:93-98.
43. Goetz CG, et al. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology 1998;50:515-517.
44. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl) 2001;102:355-363.
45. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005;58:773-776.
46. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125:391-403.
47. Harding AJ, Stimson E, Henderson JM, Halliday GM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 2002;125:2431-2445.
48. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005;4:605-610.
49. Wolters EC. Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment. Neurology 1999;52:S10-S13.
50. Moskovitz C, Moses H, III, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am J Psychiatry 1978;135:669-675.
51. Birkmayer W, Riederer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings). J Neural Transm 1975;37:175-182.
52. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340:757-763.
53. Perry EK, et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985;48:413-421.
54. Perry EK, et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 1990;55:1454-1456.
55. Bodis-Wollner I. Neuropsychological and perceptual defects in Parkinson's disease. Parkinsonism Relat Disord 2003;9 (Suppl 2):S83-S89.
56. Mosimann UP, et al. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2004;63:2091-2096.
57. Diederich NJ, et al. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol 1998;21:289-295.
58. Stebbins GT, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 2004;63:1409-1416.
59. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson's disease as disturbed external internal perceptions: focused review and a new integrative model. Mov Disord 2005;20:130-140.
60. McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
61. Paulsen JS, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 2000;54:1965-1971.